CDX
NCI-N87
Tumor indication
Esophageal, Gastric
Tumor subtype
Gastric Carcinoma
Description
NCI-N87 (Gastric Cancer CDX Model)
The NCI-N87 gastric cancer line was derived from a human gastric adenocarcinoma. It is HER2-amplified, making it highly relevant for HER2-targeted therapy research. NCI-N87 has been extensively used in biomarker and drug screening studies. Its reproducibility makes it valuable in gastric cancer pipelines.
Key Features:
- Derived from gastric adenocarcinoma.
- HER2-amplified gastric cancer model.
- Epithelial morphology.
- Tumorigenic in xenografts.
Applications:
NCI-N87 is used in HER2-targeted drug discovery for gastric cancer. Researchers apply it to biomarker validation and combination therapy testing. It supports resistance mechanism research in HER2-positive disease. Its stable biology makes it widely adopted in translational studies.
Details
- Tumor indication
- Esophageal, Gastric
- Tumor subtype
- Gastric Carcinoma
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- Proteomics, RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Lumin data
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.